Australia markets open in 9 hours 47 minutes
  • ALL ORDS

    7,759.30
    +5.00 (+0.06%)
     
  • AUD/USD

    0.7519
    +0.0024 (+0.32%)
     
  • ASX 200

    7,443.40
    +2.40 (+0.03%)
     
  • OIL

    83.96
    +0.20 (+0.24%)
     
  • GOLD

    1,801.60
    -5.20 (-0.29%)
     
  • BTC-AUD

    82,965.14
    -1,099.39 (-1.31%)
     
  • CMC Crypto 200

    1,500.74
    +1,258.06 (+518.41%)
     

Cybrexa Therapeutics to Present at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

·2-min read

NEW HAVEN, Conn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug Conjugate (PDC) tumor targeting platform, announced today that it will present the results of a preclinical study of CBX-12 (alphalex™-exatecan), the company’s lead therapeutic candidate for solid tumors, at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 7-10, 2021.

Cybrexa Therapeutics Associate Director of Biology Sophia Gayle will present results of a study evaluating the efficacy of CBX-12 in combination with PD-1- and CTLA4-targeted immune checkpoint inhibitors in preclinical cancer models. The presentation will be viewable beginning at 9:00AM ET on Thursday, October 7, to registered attendees of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.

CBX-12 is a novel treatment for solid tumors that includes a highly potent topoisomerase I inhibitor payload that is in the same class as the payloads used by antibody-drug conjugates (ADCs) ENHERTU® and TRODELVY™. In contrast to these ADCs, CBX-12 is able to target cancer cells independent of antigen expression, which could greatly expand the addressable patient populations. In May, Cybrexa initiated a Phase 1/2 clinical trial to evaluate CBX-12 in patients with advanced or metastatic refractory solid tumors to determine its safety and tolerability, maximum tolerated doses and dose limiting toxicities, and to establish the recommended Phase 2 dose.

Additional meeting information is available on AACR’s website.

About the alphalex™ Technology Platform
The Cybrexa alphalex™ technology platform – which consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent (payload) – enables antigen-independent targeting of tumors and intracellular delivery of highly potent anticancer therapies, creating therapeutics that can revolutionize the standard of care. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc. alphalex™ represents the disruptive next generation in tumor targeting. View a video of the mechanism of action of the technology at www.cybrexa.com.

About Cybrexa
Cybrexa is a privately-held biotechnology company dedicated to developing next-generation tumor-targeted cancer therapies using its alphalex™ platform. The Company’s lead candidate, CBX-12, an alphalex™-exatecan conjugate, has entered a Phase 1/2 clinical trial in patients with advanced or metastatic solid tumors. Cybrexa also has other preclinical toxin conjugate programs as well as synthetic lethality programs. Cybrexa was founded by physician-scientists and has an experienced management team that has built numerous successful life sciences companies. For more information about Cybrexa, please visit www.cybrexa.com.

Contacts

Cybrexa Therapeutics
Lisa Rehm
Email: lisa.rehm@cybrexa.com

Westwicke, an ICR Company
Investor Relations
Stephanie Carrington
Tel: 646-277-1282
Email: Stephanie.Carrington@westwicke.com

Media Relations
Mark Corbae
Tel: 203-682-8288
Email: Mark.Corbae@westwicke.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting